<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9891">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688033</url>
  </required_header>
  <id_info>
    <org_study_id>IMRTGI0001</org_study_id>
    <nct_id>NCT05688033</nct_id>
  </id_info>
  <brief_title>Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy</brief_title>
  <official_title>Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During During Neoadjuvant Chemoradiation With Capecitabine and Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project first retrospectively analyzes the intestinal dose indicators related to the&#xD;
      concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and&#xD;
      the pelvic dose indicators related to hematological toxicity, and then prospectively conducts&#xD;
      radiotherapy based on the dose indicators most closely related to toxicity. The dose is&#xD;
      limited when the plan is made to reduce the gastrointestinal and hematological toxicity of&#xD;
      rectal cancer with concurrent radiotherapy and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Actual">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Who Experienced Tumor Down-staging</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peritoneal space V15&lt;850ccï¼Œpelvic bone V10&lt;80% and normal dosimetric limitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>normal dosimetric limitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dosimetric limitation of pelvic bone and peritoneal space during radiotherapy</intervention_name>
    <description>dosimetric limitation of pelvic bone and peritoneal space during radiotherapy</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with rectal adenocarcinoma&#xD;
&#xD;
          2. Clinical staged T3/4 or any node-positive disease&#xD;
&#xD;
          3. Age of 18-75 years&#xD;
&#xD;
          4. Karnofsky Performance Status &gt; 80&#xD;
&#xD;
          5. Adequate bone marrow reserve, renal and hepatic functions&#xD;
&#xD;
          6. Without previous antitumoural chemotherapy&#xD;
&#xD;
          7. No evidence of metastatic disease&#xD;
&#xD;
          8. Written informed consent before randomization&#xD;
&#xD;
          9. UGT1A1's genotype of 6/6 or 6/7&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical staged I or IV&#xD;
&#xD;
          2. Age of &lt;18 or &gt;75 years&#xD;
&#xD;
          3. Karnofsky Performance Status &lt; 80&#xD;
&#xD;
          4. Previous pelvis radiotherapy&#xD;
&#xD;
          5. Previous antitumoural chemotherapy&#xD;
&#xD;
          6. Clinically significant internal disease&#xD;
&#xD;
          7. Refuse to write informed consent before randomization&#xD;
&#xD;
          8. UGT1A1's genotype of 7/7&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 8, 2023</last_update_submitted>
  <last_update_submitted_qc>January 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

